[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Antisense and RNAi Therapeutics Market Professional Survey Report 2016

May 2016 | 110 pages | ID: G27998FEA66EN
QYResearch

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report

Mainly covers the following product types

The segment applications including

Segment regions including (the separated region report can also be offered)
  • USA
  • China
  • Europe
  • South America
  • Japan
  • Africa
The players list (Partly, Players you are interested in can also be added)
  • Alnylam Pharmaceuticals
  • Isis Pharmaceuticals
  • Sanofi
  • Glaxosmithkline
  • Pfizer
  • Allergan
  • Antisense Therapeutics
  • Ascletis
  • AstraZeneca
  • Novartis
  • Atlantic Pharmaceuticals
  • Benitec Biopharma
  • Biogen Idec
  • Takeda Pharmaceutical
  • Bristol-Myers Squibb
  • Teva Pharmaceutical
  • Dainippon Sumitomo Pharma
  • Dicerna Pharmaceuticals
  • Enzon Pharmaceuticals
  • F. Hoffmann-La Roche
  • Gradalis
  • ICo Therapeutics
  • Kyowa Hakko Kirin
  • Marina Biotech
  • Acuitas Therapeutics
  • OncoGenex Pharmaceuticals
  • OPKO Health
  • Quark Pharmaceuticals
  • Regulus Therapeutics
  • Silence Therapeutics
  • Spectrum Pharmaceuticals
  • Sylentis
  • The Medicines Company
  • TransDerm
With no less than 15 top producers.

Data including (both global and regions): Market Size (both volume - Unit and value - million USD), Market Share, Production data, Consumption data, Trade data, Price - USD/Unit, Cost, Gross margin etc.

More detailed information, please refer to the attachment file and table of contents. If you have other requirements, please contact us, we can also offer!
1 INDUSTRY OVERVIEW OF ANTISENSE AND RNAI THERAPEUTICS

1.1 Definition and Specifications of Antisense and RNAi Therapeutics
  1.1.1 Definition of Antisense and RNAi Therapeutics
  1.1.2 Specifications of Antisense and RNAi Therapeutics
1.2 Classification of Antisense and RNAi Therapeutics
1.3 Applications of Antisense and RNAi Therapeutics
1.4 Industry Chain Structure of Antisense and RNAi Therapeutics
1.5 Industry Overview and Major Regions Status of Antisense and RNAi Therapeutics
  1.5.1 Industry Overview of Antisense and RNAi Therapeutics
  1.5.2 Global Major Regions Status of Antisense and RNAi Therapeutics
1.6 Industry Policy Analysis of Antisense and RNAi Therapeutics
1.7 Industry News Analysis of Antisense and RNAi Therapeutics

2 MANUFACTURING COST STRUCTURE ANALYSIS OF ANTISENSE AND RNAI THERAPEUTICS

2.1 Raw Material Suppliers and Price Analysis of Antisense and RNAi Therapeutics
2.2 Equipment Suppliers and Price Analysis of Antisense and RNAi Therapeutics
2.3 Labor Cost Analysis of Antisense and RNAi Therapeutics
2.4 Other Costs Analysis of Antisense and RNAi Therapeutics
2.5 Manufacturing Cost Structure Analysis of Antisense and RNAi Therapeutics
2.6 Manufacturing Process Analysis of Antisense and RNAi Therapeutics

3 TECHNICAL DATA AND MANUFACTURING PLANTS ANALYSIS OF ANTISENSE AND RNAI THERAPEUTICS

3.1 Capacity and Commercial Production Date of Global Antisense and RNAi Therapeutics Major Manufacturers in 2015
3.2 Manufacturing Plants Distribution of Global Antisense and RNAi Therapeutics Major Manufacturers in 2015
3.3 R&D Status and Technology Source of Global Antisense and RNAi Therapeutics Major Manufacturers in 2015
3.4 Raw Materials Sources Analysis of Global Antisense and RNAi Therapeutics Major Manufacturers in 2015

4 GLOBAL ANTISENSE AND RNAI THERAPEUTICS OVERALL MARKET OVERVIEW

4.1 2011-2016E Overall Market Analysis
  4.2.1 2011-2015 Global Antisense and RNAi Therapeutics Capacity and Growth Rate Analysis
  4.2.2 2015 Antisense and RNAi Therapeutics Capacity Analysis (Company Segment)
4.3 Sales Analysis
  4.3.1 2011-2015 Global Antisense and RNAi Therapeutics Sales and Growth Rate Analysis
  4.3.2 2015 Antisense and RNAi Therapeutics Sales Analysis (Company Segment)
4.4 Sales Price Analysis
  4.4.1 2011-2015 Global Antisense and RNAi Therapeutics Sales Price
  4.4.2 2015 Antisense and RNAi Therapeutics Sales Price Analysis (Company Segment)
4.5 Gross Margin Analysis
  4.5.1 2011-2015 Global Antisense and RNAi Therapeutics Gross Margin
  4.5.2 2015 Antisense and RNAi Therapeutics Gross Margin Analysis (Company Segment)

5 ANTISENSE AND RNAI THERAPEUTICS REGIONAL MARKET ANALYSIS

5.1 USA Antisense and RNAi Therapeutics Market Analysis
  5.1.1 USA Antisense and RNAi Therapeutics Market Overview
  5.1.2 USA 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis
  5.1.3 USA 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis
  5.1.4 USA 2015 Antisense and RNAi Therapeutics Market Share Analysis
5.2 China Antisense and RNAi Therapeutics Market Analysis
  5.2.1 China Antisense and RNAi Therapeutics Market Overview
  5.2.2 China 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis
  5.2.3 China 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis
  5.2.4 China 2015 Antisense and RNAi Therapeutics Market Share Analysis
5.3 Europe Antisense and RNAi Therapeutics Market Analysis
  5.3.1 Europe Antisense and RNAi Therapeutics Market Overview
  5.3.2 Europe 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis
  5.3.3 Europe 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis
  5.3.4 Europe 2015 Antisense and RNAi Therapeutics Market Share Analysis
5.4 South America Antisense and RNAi Therapeutics Market Analysis
  5.4.1 South America Antisense and RNAi Therapeutics Market Overview
  5.4.2 South America 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis
  5.4.3 South America 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis
  5.4.4 South America 2015 Antisense and RNAi Therapeutics Market Share Analysis
5.5 Japan Antisense and RNAi Therapeutics Market Analysis
  5.5.1 Japan Antisense and RNAi Therapeutics Market Overview
  5.5.2 Japan 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis
  5.5.3 Japan 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis
  5.5.4 Japan 2015 Antisense and RNAi Therapeutics Market Share Analysis
5.6 Africa Antisense and RNAi Therapeutics Market Analysis
  5.6.1 Africa Antisense and RNAi Therapeutics Market Overview
  5.6.2 Africa 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis
  5.6.3 Africa 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis
  5.6.4 Africa 2015 Antisense and RNAi Therapeutics Market Share Analysis

6 GLOBAL 2011-2016E ANTISENSE AND RNAI THERAPEUTICS SEGMENT MARKET ANALYSIS (BY TYPE)

6.1 Global 2011-2016E Antisense and RNAi Therapeutics Sales by Type
6.2 Different Types Antisense and RNAi Therapeutics Product Interview Price Analysis
6.3 Different Types Antisense and RNAi Therapeutics Product Driving Factors Analysis

7 GLOBAL 2011-2016E ANTISENSE AND RNAI THERAPEUTICS SEGMENT MARKET ANALYSIS (BY APPLICATION)

7.1 Global 2011-2016E Consumption by Application
7.2 Different Application Product Interview Price Analysis
7.3 Different Application Product Driving Factors Analysis

8 MAJOR MANUFACTURERS ANALYSIS OF ANTISENSE AND RNAI THERAPEUTICS

8.1 Alnylam Pharmaceuticals
  8.1.1 Company Profile
  8.1.2 Product Picture and Specifications
  8.1.3 Alnylam Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.1.4 Alnylam Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.2 Isis Pharmaceuticals
  8.2.1 Company Profile
  8.2.2 Product Picture and Specifications
  8.2.3 Isis Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.2.4 Isis Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.3 Sanofi
  8.3.1 Company Profile
  8.3.2 Product Picture and Specifications
  8.3.3 Sanofi 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.3.4 Sanofi 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.4 Glaxosmithkline
  8.4.1 Company Profile
  8.4.2 Product Picture and Specifications
  8.4.3 Glaxosmithkline 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.4.4 Glaxosmithkline 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.5 Pfizer
  8.5.1 Company Profile
  8.5.2 Product Picture and Specifications
  8.5.3 Pfizer 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.5.4 Pfizer 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.6 Allergan
  8.6.1 Company Profile
  8.6.2 Product Picture and Specifications
  8.6.3 Allergan 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.6.4 Allergan 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.7 Antisense Therapeutics
  8.7.1 Company Profile
  8.7.2 Product Picture and Specifications
  8.7.3 Antisense Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.7.4 Antisense Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.8 Ascletis
  8.8.1 Company Profile
  8.8.2 Product Picture and Specifications
  8.8.3 Ascletis 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.8.4 Ascletis 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.9 AstraZeneca
  8.9.1 Company Profile
  8.9.2 Product Picture and Specifications
  8.9.3 AstraZeneca 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.9.4 AstraZeneca 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.10 Novartis
  8.10.1 Company Profile
  8.10.2 Product Picture and Specifications
  8.10.3 Novartis 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.10.4 Novartis 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.11 Atlantic Pharmaceuticals
  8.11.1 Company Profile
  8.11.2 Product Picture and Specifications
  8.11.3 Atlantic Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.11.4 Atlantic Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.12 Benitec Biopharma
  8.12.1 Company Profile
  8.12.2 Product Picture and Specifications
  8.12.3 Benitec Biopharma 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.12.4 Benitec Biopharma 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.13 Biogen Idec
  8.13.1 Company Profile
  8.13.2 Product Picture and Specifications
  8.13.3 Biogen Idec 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.13.4 Biogen Idec 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.14 Takeda Pharmaceutical
  8.14.1 Company Profile
  8.14.2 Product Picture and Specifications
  8.14.3 Takeda Pharmaceutical 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.14.4 Takeda Pharmaceutical 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.15 Bristol-Myers Squibb
  8.15.1 Company Profile
  8.15.2 Product Picture and Specifications
  8.15.3 Bristol-Myers Squibb 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.15.4 Bristol-Myers Squibb 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.16 Teva Pharmaceutical
  8.16.1 Company Profile
  8.16.2 Product Picture and Specifications
  8.16.3 Teva Pharmaceutical 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.16.4 Teva Pharmaceutical 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.17 Dainippon Sumitomo Pharma
  8.17.1 Company Profile
  8.17.2 Product Picture and Specifications
  8.17.3 Dainippon Sumitomo Pharma 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.17.4 Dainippon Sumitomo Pharma 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.18 Dicerna Pharmaceuticals
  8.18.1 Company Profile
  8.18.2 Product Picture and Specifications
  8.18.3 Dicerna Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.18.4 Dicerna Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.19 Enzon Pharmaceuticals
  8.19.1 Company Profile
  8.19.2 Product Picture and Specifications
  8.19.3 Enzon Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.19.4 Enzon Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.20 F. Hoffmann-La Roche
  8.20.1 Company Profile
  8.20.2 Product Picture and Specifications
  8.20.3 F. Hoffmann-La Roche 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.20.4 F. Hoffmann-La Roche 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.21 Gradalis
  8.21.1 Company Profile
  8.21.2 Product Picture and Specifications
  8.21.3 Gradalis 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.21.4 Gradalis 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.22 ICo Therapeutics
  8.22.1 Company Profile
  8.22.2 Product Picture and Specifications
  8.22.3 ICo Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.22.4 ICo Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.23 Kyowa Hakko Kirin
  8.23.1 Company Profile
  8.23.2 Product Picture and Specifications
  8.23.3 Kyowa Hakko Kirin 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.23.4 Kyowa Hakko Kirin 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.24 Marina Biotech
  8.24.1 Company Profile
  8.24.2 Product Picture and Specifications
  8.24.3 Marina Biotech 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.24.4 Marina Biotech 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.25 Acuitas Therapeutics
  8.25.1 Company Profile
  8.25.2 Product Picture and Specifications
  8.25.3 Acuitas Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.25.4 Acuitas Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.26 OncoGenex Pharmaceuticals
  8.26.1 Company Profile
  8.26.2 Product Picture and Specifications
  8.26.3 OncoGenex Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.26.4 OncoGenex Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.27 OPKO Health
  8.27.1 Company Profile
  8.27.2 Product Picture and Specifications
  8.27.3 OPKO Health 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.27.4 OPKO Health 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.28 Quark Pharmaceuticals
  8.28.1 Company Profile
  8.28.2 Product Picture and Specifications
  8.28.3 Quark Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.28.4 Quark Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.29 Regulus Therapeutics
  8.29.1 Company Profile
  8.29.2 Product Picture and Specifications
  8.29.3 Regulus Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.29.4 Regulus Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.30 Silence Therapeutics
  8.30.1 Company Profile
  8.30.2 Product Picture and Specifications
  8.30.3 Silence Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.30.4 Silence Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.31 Spectrum Pharmaceuticals
  8.31.1 Company Profile
  8.31.2 Product Picture and Specifications
  8.31.3 Spectrum Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.31.4 Spectrum Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.32 Sylentis
  8.32.1 Company Profile
  8.32.2 Product Picture and Specifications
  8.32.3 Sylentis 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.32.4 Sylentis 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.33 The Medicines Company
  8.33.1 Company Profile
  8.33.2 Product Picture and Specifications
  8.33.3 The Medicines Company 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.33.4 The Medicines Company 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis
8.34 TransDerm
  8.34.1 Company Profile
  8.34.2 Product Picture and Specifications
  8.34.3 TransDerm 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.34.4 TransDerm 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis

9 DEVELOPMENT TREND OF ANALYSIS OF MARKET

9.1 Global Market Trend Analysis
  9.1.1 Global 2016-2021 Market Size (Volume and Value) Forecast
  9.1.2 Global 2016-2021 Sales Price Forecast
  9.1.3 Global 2016-2021 Gross Margin Forecast
9.2 Regional Market Trend
  9.2.1 USA 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast
  9.2.2 China 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast
  9.2.3 Europe 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast
  9.2.4 South America 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast
  9.2.5 Japan 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast
  9.2.6 Africa 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast
9.3 Market Trend (Product type)
9.4 Market Trend (Application)

10 ANTISENSE AND RNAI THERAPEUTICS MARKETING MODEL ANALYSIS

10.1 Antisense and RNAi Therapeutics Regional Marketing Model Analysis
10.2 Antisense and RNAi Therapeutics International Trade Model Analysis
10.3 Traders or Distributors with Contact Information of Antisense and RNAi Therapeutics by Regions
10.4 Antisense and RNAi Therapeutics Supply Chain Analysis

11 CONSUMERS ANALYSIS OF ANTISENSE AND RNAI THERAPEUTICS

11.1 Consumer 1 Analysis
11.2 Consumer 2 Analysis
11.3 Consumer 3 Analysis
11.4 Consumer 4 Analysis

12 NEW PROJECT INVESTMENT FEASIBILITY ANALYSIS OF ANTISENSE AND RNAI THERAPEUTICS

12.1 New Project SWOT Analysis of Antisense and RNAi Therapeutics
12.2 New Project Investment Feasibility Analysis of Antisense and RNAi Therapeutics

13 CONCLUSION OF THE GLOBAL ANTISENSE AND RNAI THERAPEUTICS MARKET PROFESSIONAL SURVEY REPORT 2016


More Publications